搜索筛选:
搜索耗时0.0711秒,为你在为你在102,285,761篇论文里面共找到 7 篇相符的论文内容
发布年度:
The oral c-Met inhibitor MSC2156119J as monotherapy vs sorafenib in Asian patients with Met-positive
[会议论文] 作者：Shukui Qin,Ann-Lii Cheng,Ho Yeong Lim,Lianzhe Xu,Cindy Li,Friedhelm Bladt,
来源：第十七届全国临床肿瘤学大会暨2014年CSCO学术年会 年份：2014
...
The oral c-Met inhibitor MSC2156119J as monotherapy vs sorafenib in Asian patients with Met-positive
[会议论文] 作者：Shukui Qin,Ann-Lii Cheng,Ho Yeong Lim,Lianzhe Xu,Cindy Li,Friedhelm Bladt,
来源：第十七届全国临床肿瘤学大会暨2014年CSCO学术年会 年份：2014
Objective: Advanced hepatocellular carcinoma (HCC) is a leading cause of cancer death, particularly in Asia where ～80％ of HCC incidences occur.Although sorafenib is the recommended treatment, it is no...
[会议论文] 作者：Shukui Qin,Ho yeong Lim,Baek-yeol Ryoo,Cindy Li,Huiling Xiong,Christian Ihling,Ann-lii Cheng,
来源：第十八届全国临床肿瘤学大会暨2015年CSCO学术年会 年份：2015
Objective: The overall prognosis of advanced hepatocellular cancer (HCC) remains poor, with c-Met abnormalities associated with a particularly poor prognosis.The highly selective c-Met inhibitor tepot...
First-line tepotinib (MSC2156119J), an oral c-Met inhibitor, versus sorafenib in Asian patients with
[会议论文] 作者：Shukui Qin,Ho yeong Lim,Baek-yeol Ryoo,Cindy Li,Huiling Xiong,Andreas Johne,Ann-lii Cheng,
来源：第十八届全国临床肿瘤学大会暨2015年CSCO学术年会 年份：2015
Background: HCC, a poor-prognosis disease for which the only approved drug is sorafenib, has a high unmet need.Factors associated with tumor aggressiveness in advanced HCC include c-Met amplification/...
Activity of the c-Met inhibitor tepotinib (MSC2156119J) in combination with gefitinib in Asian patie
[会议论文] 作者：Yi-long Wu,Keunchil Park,Dong-wan Kim,Ross a.Soo,Huiling Xiong,Cindy Li,Christian Ihling,James chih-hsin,
来源：第十八届全国临床肿瘤学大会暨2015年CSCO学术年会 年份：2015
Objective: c-Met abnormalities can cause resistance to EGFR TKIs in EGFR mutant NSCLC patients (pts).The highly selective c-Met inhibitor tepotinib (MSC2156...
Phase Ⅱ trial comparing tepotinib + gefitinib with cisplatin + pemetrexed in Asian patients with gef
[会议论文] 作者：Yilong Wu,Keunchil Park,Dongwan Kim,Ross a.Soo,Cindy Li,Huiling Xiong,Christian Ihling,James chih-hsin,
来源：第十八届全国临床肿瘤学大会暨2015年CSCO学术年会 年份：2015
Background: The combination of the highly selective c-Met inhibitor tepotinib (MSC2156119J) + gefitinib was shown to be well tolerated and have antitumor activity possibly associated with c-Met-positi...
Activity of the c-Met inhibitor tepotinib (MSC2156119J) in combination with gefitinib in Asian patie
[会议论文] 作者：Yi-long Wu,Keunchil Park,Dong-wan Kim,Ross a.Soo,Cindy Li,Huiling Xiong,Christian Ihling,James chih-hsin,
来源：第十八届全国临床肿瘤学大会暨2015年CSCO学术年会 年份：2015
Objective: c-Met abnormalities can cause resistance to EGFR TKIs in EGFR mutant NSCLC patients (pts).The highly selective c-Met inhibitor tepotinib (MSC2156119J) had promising activity in a phase Ⅰ tr...
相关搜索：
